PRKN and cancer: The first PCR2-targeting PROTAC was composed of a target protein-binding ligand (EED) and an E3 ubiquitin ligase ligand (VHL) and could degrades PCR2 in cancer cells and inhibit cell proliferation in PRC2-dependent cancer cells.